The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression

Trends in Molecular Medicine

Volumn 15, Issue 8, 2009, Pages 333-343

  Gao, Dingcheng ^a   Mittal, Vivek ^a,b  

^a LEHMAN BROTHERS   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOCETAXEL; FLUOROURACIL; IMATINIB; PACLITAXEL; RETINOIC ACID; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN ANTIBODY; VASCULOTROPIN RECEPTOR 1 ANTIBODY; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

ARTICLE; BREAST CANCER; CANCER INVASION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MESENCHYMAL STEM CELL; METASTASIS; NONHUMAN; OVARY CANCER; TUMOR; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; BONE MARROW CELLS; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; STEM CELLS;

MURINAE;

EID: 68649089967     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.06.006     Document Type: Article

References (115)

1. Albini A., and Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 7 (2007) 139-147
2. Joyce J.A., and Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9 (2009) 239-252
3. McAllister S.S., et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133 (2008) 994-1005
4. Gao D., et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319 (2008) 195-198
5. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7 (2005) 513-520
6. Shaked Y., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 (2006) 1785-1787
7. Shaked Y., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14 (2008) 263-273
8. Shojaei F., and Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res. 68 (2008) 5501-5504
9. Murdoch C., et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8 (2008) 618-631
10. Shojaei F., et al. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol. 18 (2008) 372-378
11. Kopp H.G., et al. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 13 (2006) 175-181
12. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
13. Seandel M., et al. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell 13 (2008) 181-183
14. Qiu W., et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 40 (2008) 650-655
15. Weinberg R.A. Coevolution in the tumor microenvironment. Nat. Genet. 40 (2008) 494-495
16. Ferrara N., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004) 391-400
17. Olsson A.K., et al. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7 (2006) 359-371
18. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
19. Yin T., and Li L. The stem cell niches in bone. J. Clin. Invest. 116 (2006) 1195-1201
20. Wilson A., and Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 6 (2006) 93-106
21. Adams G.B., et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439 (2006) 599-603
22. Kopp H.G., et al. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20 (2005) 349-356
23. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
24. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004) 409-421
25. + myeloid cells that promote metastasis. Cancer Cell 13 (2008) 23-35
26. Lin E.Y., et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001) 727-740
27. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 (2005) 211-226
28. + hemangiocytes. Nat. Med. 12 (2006) 557-567
29. Grunewald M., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
30. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7 (2005) 870-879
31. Conejo-Garcia J.R., et al. Vascular leukocytes contribute to tumor vascularization. Blood 105 (2005) 679-681
32. Soucek L., et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13 (2007) 1211-1218
33. Nozawa H., et al. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 12493-12498
34. Torisu H., et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int. J. Cancer 85 (2000) 182-188
35. Bingle L., et al. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196 (2002) 254-265
36. Lewis C.E., and Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66 (2006) 605-612
37. Bergers G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744
38. Hamano Y., et al. Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αV β3 integrin. Cancer Cell 3 (2003) 589-601
39. Stockmann C., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456 (2008) 814-818
40. Lamagna C., and Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J. Leukoc. Biol. 80 (2006) 677-681
41. Lindahl P., et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277 (1997) 242-245
42. Greenberg J.I., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456 (2008) 809-813
43. Theoharides T.C., and Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 25 (2004) 235-241
44. Norrby K. Mast cells and angiogenesis. APMIS 110 (2002) 355-371
45. Asahara T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
46. Peters B.A., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11 (2005) 261-262
47. Minami E., et al. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation 112 (2005) 2951-2958
48. Garcia-Barros M., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
49. Duda D.G., et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107 (2006) 2774-2776
50. Lyden D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
51. Rajantie I., et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104 (2004) 2084-2086
52. Machein M.R., et al. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 13 (2003) 582-597
53. De Palma M., et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9 (2003) 789-795
54. Gothert J.R., et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 104 (2004) 1769-1777
55. Ziegelhoeffer T., et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res. 94 (2004) 230-238
56. Voswinckel R., et al. Circulating vascular progenitor cells do not contribute to compensatory lung growth. Circ. Res. 93 (2003) 372-379
57. He Y., et al. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 64 (2004) 3737-3740
58. Purhonen S., et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6620-6625
59. Kim S.J., et al. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am. J. Pathol. 174 (2009) 1972-1980
60. Kerbel R.S., et al. Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) E54
61. Ruzinova M.B., et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4 (2003) 277-289
62. Li H., et al. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res. 64 (2004) 6137-6143
63. Spring H., et al. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18111-18116
64. Nolan D.J., et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 21 (2007) 1546-1558
65. Shaked Y., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005) 101-111
66. Bertolini F., et al. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6 (2006) 835-845
67. Larrivee B., et al. Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J. Immunol. 175 (2005) 2890-2899
68. Jankovic V., et al. Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1260-1265
69. Perry S.S., et al. Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood 110 (2007) 2351-2360
70. Singh Jaggi J., et al. Selective α-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One 2 (2007) e267
71. Lee S., et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130 (2007) 691-703
72. Yoder M.C., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109 (2007) 1801-1809
73. Prindull G.A., and Fibach E. Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells?. Exp. Hematol. 35 (2007) 691-701
74. Gabrilovich D.I., et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67 (2007) 425
75. Tu S., et al. Overexpression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14 (2008) 408-419
76. Gabrilovich D.I., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996) 1096-1103
77. Cheng P., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205 (2008) 2235-2249
78. Sinha P., et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179 (2007) 977-983
79. + T cell tolerance in cancer. Nat. Med. 13 (2007) 828-835
80. Kusmartsev S., et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63 (2003) 4441-4449
81. + myeloid cells. Nat. Biotechnol. 25 (2007) 911-920
82. Hall B., et al. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb. Exp. Pharmacol. 180 (2007) 263-283
83. Karnoub, A.E. et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. In Nature, 557-563
84. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8 (1989) 98-101
85. Kaplan R.N., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
86. Hiratsuka S., et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8 (2006) 1369-1375
87. Hiratsuka S., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10 (2008) 1349-1355
88. Erler J.T., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15 (2009) 35-44
89. Heissig B., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 (2002) 625-637
90. Ceradini D.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004) 858-864
91. Ahn G.O., and Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13 (2008) 193-205
92. Du R., et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008) 206-220
93. Ellis L.M., and Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8 (2008) 579-591
94. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
95. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008) 592-603
96. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23 (2005) 939-952
97. Xian X., et al. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116 (2006) 642-651
98. Almand B., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166 (2001) 678-689
99. Young M.R., and Lathers D.M. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int. J. Immunopharmacol. 21 (1999) 241-252
100. Talmadge J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13 (2007) 5243-5248
101. Melani C., et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67 (2007) 11438-11446
102. Furstenberger G., et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer 94 (2006) 524-531
103. Shaked Y., and Kerbel R.S. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 67 (2007) 7055-7058
104. + cells in cancer animal models. Int. Immunol. 18 (2006) 1-9
105. de Visser K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006) 24-37
106. Waldhauer I., and Steinle A. NK cells and cancer immunosurveillance. Oncogene 27 (2008) 5932-5943
107. Vigneri P., and Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7 (2001) 228-234
108. Carella A.M., and Lerma E. Imatinib mesylate in chronic myeloid leukemia. Curr. Stem Cell Res. Ther. 2 (2007) 249-251
109. Holash J., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11393-11398
110. Tonra J.R., et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 12 (2006) 2197-2207
111. Nefedova Y., et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67 (2007) 11021-11028
112. Batchelor T.T., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
113. Liao F., et al. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 62 (2002) 2567-2575
114. Aharinejad S., et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64 (2004) 5378-5384
115. Zeisberger S.M., et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95 (2006) 272-281